Ovarian Cancer Coverage from Every Angle

Maintenance Olaparib in Advanced Ovarian Cancer: SOLO-1 Long-Term Survival Update

By: Sarah Campen, PharmD
Posted: Friday, October 23, 2020

Almost half of patients who received maintenance olaparib for newly diagnosed BRCA-mutated advanced ovarian cancer remained disease-free after 5 years, according to data from a long-term follow-up of the SOLO-1 trial presented during the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 811MO). Only 20% of patients who received a placebo were disease-free after 5 years.

“These results represent a significant step forward in the treatment of newly diagnosed advanced ovarian cancer and give us real hope for more long-term survivors,” stated Susana Banerjee, MBBS, PhD, of the Royal Marsden Hospital NHS Foundation Trust and Institute of Cancer Research, London, in a Royal Marsden press release.

In this phase III study, 391 patients were randomly assigned to receive olaparib (n = 260) or placebo (n = 131). Patients received maintenance olaparib at 300 mg twice daily or placebo for up to 2 years or until disease progression. The duration of treatment in each arm was 24.6 and 13.9 months, respectively.

After a median follow-up of 4.8 years in the olaparib arm and 5.0 years in the placebo arm, 48.3% of patients treated with olaparib had not experienced disease progression and were still living with stable disease compared with 20.5% of those taking placebo. The median progression-free survival was 56 versus 14 months, respectively. Among patients in complete response at baseline, the risk of disease recurrence or death was reduced by 63%. The safety profile of olaparib was consistent with previous reports.

“SOLO-1 has given us the evidence to show that as a first-line therapy, it can have substantial benefit for patients earlier in the cancer pathway,” concluded Dr. Banerjee.

Disclosure: For full disclosure of the study authors, visit oncologypro.esmo.org.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.